Program
ABBV-1758
A development code.
In AbbVie's pipeline, Pyroglutamate (3pE) Aβ
. Its studies are mostly in Alzheimer Disease, led by AbbVie.
Furthest: phase 2, since May 15, 20261 company-led study, 1 open or runningNext primary completion: Oct 2030 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AbbVie | 11 open or running | phase 2since May 15, 2026 | May 15, 2026 | Oct 2030phase 2 · NCT07599670 |
- Named in AbbVie’s own pipeline as
ABBV-1758
, phase 1, as of Jul 30, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 15, 2026First study: phase 2 study in Alzheimer DiseaseFirst studyNCT07599670 · 210 planned · United States, China
Ahead
- Oct 2030Primary completion: phase 2 study in Alzheimer DiseaseNCT07599670
TargetBeta
“Pyroglutamate (3pE) Aβ”the company's pipeline, read by Claude · source
Other programs on APP
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07599670Alzheimer Disease · United States, China | 2 | Recruiting | Oct 2030 | 210 |
How it is read
Names in the registry
- “ABBV-1758”, 2 entries
Codes read as this program: ABBV1758.
Conditions, from the studies’ own filings
- Alzheimer Disease, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.